NY-BREGAL-SAGEMOUNT
10.1.2023 09:01:39 CET | Business Wire | Press release
Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, today announced a strategic growth investment in Enhesa (the “Company”), a leading provider of regulatory and sustainability intelligence worldwide. As part of the transaction, Sagemount will acquire ICG’s minority stake in Enhesa, with existing investor CGE Partners (“CGE”) retaining its majority stake in the Company. Financial terms of the transaction were not disclosed.
With its global headquarters in Brussels, Belgium and U.S. headquarters in Arlington, VA, Enhesa empowers multinational corporations worldwide to help create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions, supported by a team of over 100 in-house legal experts. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future.
“We are thrilled to be partnering with Sagemount as we enter our next stage of growth,” said Peter Schramme, CEO of Enhesa. “With their and CGE’s support and deep industry expertise, we believe we are well-positioned to further invest in our current offerings as well as accelerate new content coverage, use cases, and customer verticals.”
“We see tremendous growth ahead for Enhesa as a result of the Company’s strong product-market fit and tangible customer ROI,” said Pavan Tripathi, Partner at Sagemount. “Enhesa has an impressive track record of consistently retaining and growing its customer relationships as well as expanding new content offerings and jurisdictional coverage through both organic and inorganic growth initiatives. We are excited to be working with Peter, the Enhesa team, and CGE.”
David Greenbaum, Vice President at Sagemount, added, “For enterprises that operate, manufacture, and sell globally, Enhesa is by far the leading third-party content provider, allowing companies to monitor relevant Environmental, Health, & Safety (“EHS”) and other regulations across the enterprise significantly faster and more accurately than internal teams or disparate, regional third-party content providers.”
"We have enjoyed a highly successful partnership with Enhesa since acquiring the Company in 2020. Under CGE’s ownership to date, Enhesa has meaningfully scaled its business, expanded its industry-leading regulatory compliance content set from EHS to also include Product Compliance and Sustainability Intelligence, and completed five strategic add-on acquisitions," CGE commented. "We look forward to continuing to support Enhesa in its next chapter of growth alongside Sagemount."
Sagemount’s investment was led by Pavan Tripathi, Sandeep Swaminathan, David Greenbaum, Harrison Boyajian, and Stephanie Li. Sagemount was advised by Raymond James and Goodwin Procter. Enhesa and CGE were advised by Houlihan Lokey and Travers Smith.
About Enhesa
Enhesa is the leading provider of regulatory and sustainability intelligence worldwide. Headquartered in Brussels, with offices in Washington, DC, Williamsport, PA, Toronto, the United Kingdom, Tokyo, Shanghai, and Portugal, Enhesa empowers multinational corporations worldwide to create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future. For more information on Enhesa, go to the firm's website at www.enhesa.com.
About Sagemount
Bregal Sagemount is a leading growth-focused private capital firm with more than $6.0 billion of capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 70 companies in a variety of sectors, including software, information / data services, financial technology & specialty finance, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York, Palo Alto, and Dallas. For more information, visit the Sagemount website: www.sagemount.com or follow us on LinkedIn.
About CGE
CGE Partners is a European mid-market investment fund. CGE invests in tech-enabled businesses facilitating the transition to a more digital, renewable, secure, and compliant future, providing capital and expertise to accelerate expansion in global markets. For more information, visit the CGE website: https://cge-partners.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom